Browse EV MemProt Atlas
- Frequency:
- literature support frequency.
- EVMP score:
annotation confidence score.
Extremely high >= 0.85High >= 0.70Medium >= 0.55Low >= 0.40
| UniProt ID | Protein names | Protein classification | Transmembrane count | Related Diseases | Mediation categories | Download | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| HYI | Q5T013 | Putative hydroxypyruvate isomerase (EC 5.3.1.22) (Endothelial cell apoptosis protein E-CE1) | EnzymesMetabolic proteinsPredicted intracellular proteins | Other mediation | 1 | 0.38 | ||||
| I13R2 | Q14627 | Interleukin-13 receptor subunit alpha-2 (IL-13 receptor subunit alpha-2) (IL-13R subunit alpha-2) (IL-13R-alpha-2) (IL-13RA2) (Interleukin-13-binding protein) (CD antigen CD213a2) | 1 | AsthmaBrain cancerOesophagitis | Clinical-translation mediationFusion and delivery mediationImmune mediation | 1 | 0.38 | |||
| IFRD1 | O00458 | Interferon-related developmental regulator 1 (Nerve growth factor-inducible protein PC4) | Predicted intracellular proteinsPredicted membrane proteins | Other mediation | 1 | 0.38 | ||||
| IL1R1 | P14778 | Interleukin-1 receptor type 1 (IL-1R-1) (IL-1RT-1) (IL-1RT1) (EC 3.2.2.6) (CD121 antigen-like family member A) (Interleukin-1 receptor alpha) (IL-1R-alpha) (Interleukin-1 receptor type I) (p80) (CD antigen CD121a) [Cleaved into: Interleukin-1 receptor type 1, membrane form (mIL-1R1) (mIL-1RI); Interleukin-1 receptor type 1, soluble form (sIL-1R1) (sIL-1RI)] | Cancer-related genesCD markersEnzymesFDA approved drug targetsHuman disease related genesPredicted membrane proteinsPredicted secreted proteinsTransporters | 1 | Rheumatoid arthritisCOVID-19 | Clinical-translation mediationFusion and delivery mediationImmune mediation | 1 | 0.38 | ||
| IL4RA | P24394 | Interleukin-4 receptor subunit alpha (IL-4 receptor subunit alpha) (IL-4R subunit alpha) (IL-4R-alpha) (IL-4RA) (CD antigen CD124) [Cleaved into: Soluble interleukin-4 receptor subunit alpha (Soluble IL-4 receptor subunit alpha) (Soluble IL-4R-alpha) (sIL4Ralpha/prot) (IL-4-binding protein) (IL4-BP)] | Cancer-related genesCD markersFDA approved drug targetsHuman disease related genesPlasma proteinsPredicted intracellular proteinsPredicted membrane proteinsPredicted secreted proteinsTransporters | 1 | AsthmaAtopic eczemaIdiopathic interstitial pneumonitisSolid tumour/cancerSystemic sclerosis | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediationImmune mediationMetabolism mediation | 1 | 0.38 | ||
| IL7RA | P16871 | Interleukin-7 receptor subunit alpha (IL-7 receptor subunit alpha) (IL-7R subunit alpha) (IL-7R-alpha) (IL-7RA) (CDw127) (CD antigen CD127) | Cancer-related genesCD markersDisease related genesHuman disease related genesPredicted intracellular proteinsPredicted membrane proteins | 1 | Atopic eczemaDiabetes mellitusHuman immunodeficiency virus diseaseType 2 diabetes mellitus | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediationImmune mediation | 1 | 0.38 | ||
| IMPG1 | Q17R60 | Interphotoreceptor matrix proteoglycan 1 (Interphotoreceptor matrix proteoglycan of 150 kDa) (IPM-150) (Sialoprotein associated with cones and rods) | Disease related genesHuman disease related genesPredicted intracellular proteinsPredicted secreted proteins | Other mediation | 1 | 0.38 | ||||
| IQGA2 | Q13576 | Ras GTPase-activating-like protein IQGAP2 | Plasma proteinsPredicted intracellular proteinsPredicted membrane proteins | Fusion and delivery mediationImmune mediationReceptor-signaling mediation | 1 | 0.38 | ||||
| ISK13 | Q1W4C9 | Serine protease inhibitor Kazal-type 13 (Hepatitis B virus DNA polymerase transactivated serine protease inhibitor) (Hespintor) (Serine protease inhibitor Kazal-type 5-like 3) | Predicted intracellular proteinsPredicted secreted proteins | Other mediation | 1 | 0.38 | ||||
| ISLR | O14498 | Immunoglobulin superfamily containing leucine-rich repeat protein | Predicted secreted proteins | Immune mediation | 1 | 0.38 | ||||
| ITA9 | Q13797 | Integrin alpha-9 (Integrin alpha-RLC) | Human disease related genesPredicted intracellular proteinsPredicted membrane proteins | 1 | Adhesion and uptake mediationFusion and delivery mediationImmune mediation | 1 | 0.38 | |||
| JMJD4 | Q9H9V9 | 2-oxoglutarate and iron-dependent oxygenase JMJD4 (EC 1.14.11.-) (JmjC domain-containing protein 4) (Jumonji domain-containing protein 4) (Lysyl-hydroxylase JMJD4) | Predicted intracellular proteins | Metabolism mediation | 1 | 0.38 | ||||
| K1958 | Q8N8K9 | Uncharacterized protein KIAA1958 | Predicted intracellular proteins | Other mediation | 1 | 0.38 | ||||
| K2C1B | Q7Z794 | Keratin, type II cytoskeletal 1b (Cytokeratin-1B) (CK-1B) (Keratin-77) (K77) (Type-II keratin Kb39) | Plasma proteinsPredicted intracellular proteins | Other mediation | 1 | 0.38 | ||||
| KANK3 | Q6NY19 | KN motif and ankyrin repeat domain-containing protein 3 (Ankyrin repeat domain-containing protein 47) | Predicted intracellular proteins | Fusion and delivery mediation | 1 | 0.38 | ||||
| KCC1B | Q6P2M8 | Calcium/calmodulin-dependent protein kinase type 1B (EC 2.7.11.17) (CaM kinase I beta) (CaM kinase IB) (CaM-KI beta) (CaMKI-beta) (Pregnancy up-regulated non-ubiquitously-expressed CaM kinase) | EnzymesMetabolic proteinsPredicted intracellular proteins | Other mediation | 1 | 0.38 | ||||
| KCC2A | Q9UQM7 | Calcium/calmodulin-dependent protein kinase type II subunit alpha (CaM kinase II subunit alpha) (CaMK-II subunit alpha) (EC 2.7.11.17) | Disease related genesEnzymesHuman disease related genesPlasma proteinsPotential drug targetsPredicted intracellular proteinsPredicted membrane proteins | Clinical-translation mediationFusion and delivery mediationImmune mediationReceptor-signaling mediation | 1 | 0.38 | ||||
| KCC2G | Q13555 | Calcium/calmodulin-dependent protein kinase type II subunit gamma (CaM kinase II subunit gamma) (CaMK-II subunit gamma) (EC 2.7.11.17) | Disease related genesEnzymesHuman disease related genesPlasma proteinsPotential drug targetsPredicted intracellular proteinsPredicted membrane proteinsTransporters | Clinical-translation mediationFusion and delivery mediationImmune mediationReceptor-signaling mediation | 1 | 0.38 | ||||
| KCNQ1 | P51787 | Potassium voltage-gated channel subfamily KQT member 1 (IKs producing slow voltage-gated potassium channel subunit alpha KvLQT1) (KQT-like 1) (Voltage-gated potassium channel subunit Kv7.1) | Disease related genesFDA approved drug targetsHuman disease related genesPlasma proteinsPredicted intracellular proteinsPredicted membrane proteinsTransportersVoltage-gated ion channels | 6 | Hypertension | Clinical-translation mediationFusion and delivery mediationImmune mediationReceptor-signaling mediation | 1 | 0.38 | ||
| KCNS3 | Q9BQ31 | Delayed-rectifier potassium channel regulatory subunit KCNS3 (Delayed-rectifier K(+) channel alpha subunit 3) (Delayed-rectifier potassium channel subunit Kv9.3) (Kv9.3) (Potassium voltage-gated channel subfamily S member 3) | Predicted intracellular proteinsPredicted membrane proteinsTransportersVoltage-gated ion channels | 6 | Fusion and delivery mediationMetabolism mediation | 1 | 0.38 | |||
| KI21B | O75037 | Kinesin-like protein KIF21B | Plasma proteinsPredicted intracellular proteins | Fusion and delivery mediationImmune mediation | 1 | 0.38 | ||||
| KI26A | Q9ULI4 | Kinesin-like protein KIF26A | Predicted intracellular proteins | Fusion and delivery mediationImmune mediation | 1 | 0.38 | ||||
| KIF19 | Q2TAC6 | Kinesin-like protein KIF19 | Predicted intracellular proteins | Fusion and delivery mediationImmune mediation | 1 | 0.38 | ||||
| KLHL5 | Q96PQ7 | Kelch-like protein 5 | Plasma proteinsPredicted intracellular proteins | Immune mediationMetabolism mediation | 1 | 0.38 | ||||
| KLHL6 | Q8WZ60 | Kelch-like protein 6 | Predicted intracellular proteins | Immune mediation | 1 | 0.38 |